An argument that this water-heater specialist has room to run.
A thorough review of why this asset manager has sunny days ahead.
A light R&D budget, a technology that may not be commercially viable, and a stock prone to promotion make one investor skeptical of BioTime's prospects.
The thesis for why the No. 2 time share player is worth a look.
Here's why the market may be overlooking the truckstop operator.
A look at why the company is being overlooked by Wall Street.
The grocer's shares are looking appetizing at current prices.
The market isn't fully recognizing the strength of GD's business.
The company's strong franchise and cash-generating abilities are being undervalued by the market right now.
The company's potential is being missed by the Wall Street analyst crowd.
Earnings may look good at GE, but trouble lurks on its balance sheet.
A rigorous rundown of why Walgreen is positioned for gains.